Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Todd M BauerArmando SantoroChia-Chi LinIgnacio Garrido-LagunaMarkus JoergerRichard GreilAnna SpreaficoThomas YauMaria-Elisabeth GoebelerMarie Luise Hütter-KrönkeAntonella PerottiPierre-Eric JuifDarlene LuLouise BarysViviana CremascoMarc PelletierHelen EvansClaire FabreToshikiko DoiPublished in: Journal for immunotherapy of cancer (2023)
NCT02947165.